Investigation of Nonneoplastic Neurologic Disorders with PET and MRI.

Neuroimaging with positron emission tomography (PET) provides metabolic and molecular information that cannot be obtained from other imaging modalities and provides novel insights into the pathogenesis and diagnosis of a diverse array of neurologic diseases. As the library of novel PET ligands expands, so does the potential role for PET in the study of neurologic disease. The emergence of PET amyloid imaging reveals the incredible potential for PET neuroimaging. Recent technical advances in our ability to combine structural MR imaging data with functional and molecular PET data have enhanced the power of PET for the study of the brain. Thus, PET and MR imaging should continue to play an expanding role in the diagnosis and investigation of neurologic disease conditions.

[1]  D E Kuhl,et al.  Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method , 1984, Annals of neurology.

[2]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[3]  C. Patlak,et al.  Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.

[4]  David Eidelberg,et al.  Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. , 2008, Brain : a journal of neurology.

[5]  R. Duncan Epilepsy, cerebral blood flow, and cerebral metabolic rate. , 1992, Cerebrovascular and brain metabolism reviews.

[6]  J. Constantinidis,et al.  Pick’s Disease , 1974 .

[7]  PET imaging in Parkinsonism. , 1993 .

[8]  R. Worth,et al.  Comparative study of interictal PET and ictal SPECT in complex partial seizures , 1997, Acta neurologica Scandinavica.

[9]  H. Ruottinen,et al.  [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. , 2001, Synapse.

[10]  L F Quesney,et al.  False lateralization by surface EEG of seizure onset in patients with temporal lobe epilepsy and gross focal cerebral lesions , 1987, Annals of neurology.

[11]  Scott T. Grafton,et al.  A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease , 1990, Annals of neurology.

[12]  J. Pruim,et al.  Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease , 2005, Neurology.

[13]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[14]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[15]  Richard S. J. Frackowiak,et al.  The identification of presymptomatic parkinsonism: Clinical and {18F}dopa positron emission tomography studies in an irish kindred , 1992, Annals of neurology.

[16]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[17]  M. Viitanen,et al.  Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease , 2008, Annals of neurology.

[18]  Nelleke Tolboom,et al.  Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.

[19]  M. Viitanen,et al.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.

[20]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[21]  K. Gwinn‐Hardy,et al.  The role of radiotracer imaging in Parkinson disease , 2005, Neurology.

[22]  Robert M. Kessler,et al.  Imaging methods for evaluating brain function in man , 2003, Neurobiology of Aging.

[23]  H. Rusinek,et al.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[25]  C D Marsden,et al.  Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography , 1986, Movement disorders : official journal of the Movement Disorder Society.

[26]  R Harrop,et al.  Positron emission tomography and histopathology in Pick's disease , 1987, Neurology.

[27]  G. Small,et al.  Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.

[28]  W. Jagust,et al.  Longitudinal studies of regional cerebral metabolism in Alzheimer's disease , 1988, Neurology.

[29]  Naokazu Miyamoto,et al.  Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  P. Crandall,et al.  Comparative localization of epileptic foci in partial epilepsy by PCT and EEG. , 1982, Annals of neurology.

[31]  W. Jagust,et al.  Reduced Temporal Lobe Glucose Metabolism in Aging , 1995, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[32]  Henry Rusinek,et al.  Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer’s disease , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  A J Lees,et al.  Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography. , 2001, Archives of neurology.

[34]  A. Alavi,et al.  Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography: evolution over the past 2 decades. , 1991, Seminars in nuclear medicine.

[35]  P. Maquet,et al.  Contribution of positron emission tomography to the investigation of epilepsies of frontal lobe origin. , 1992, Advances in neurology.

[36]  Dong Young Lee,et al.  Topographic Patterns of Brain Functional Impairment Progression According to Clinical Severity Staging in 116 Alzheimer Disease Patients: FDG-PET Study , 2007, Alzheimer disease and associated disorders.

[37]  C. Markham,et al.  Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease , 1984, Annals of neurology.

[38]  L. Mansi,et al.  CORTICAL ABNORMALITIES IN ALZHEIMER'S DISEASE , 1984, Annals of neurology.

[39]  Michael Channing,et al.  {18F}fluorodeoxyglucose positron emission tomography in refractory complex partial seizures , 1983, Annals of neurology.

[40]  R S Frackowiak,et al.  Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.

[41]  I Lemahieu,et al.  Cerebral oxygen metabolism in patients with progressive supranuclear palsy: a positron emission tomography study. , 1997, European neurology.

[42]  U Ruotsalainen,et al.  PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[43]  A. Alavi Functional and anatomic studies of head injury. , 1989, The Journal of neuropsychiatry and clinical neurosciences.

[44]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.

[45]  Hans Clusmann,et al.  THE SURGERY OF EPILEPSY , 2008, Neurosurgery.

[46]  Controlling for Cerebral Atrophy in Positron Emission Tomography Data , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  A. Lang,et al.  Striatal dopamine distribution in Parkinsonian patients during life , 1985, Journal of the Neurological Sciences.

[48]  I. Fried,et al.  Pick's Disease: A Clinical, Computed Tomographic, and Histologic Study With Golgi Impregnation Observations , 1982 .

[49]  B. Choe,et al.  Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis , 2005, Neuroscience Letters.

[50]  Hiroyuki Okada,et al.  Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: A double‐tracer positron emission tomography study , 1999, Annals of neurology.

[51]  K. Lindahl-Kiessling,et al.  USE AND ABUSE OF ELECTROENCEPHALOGRAPHY. , 1964, Lancet.

[52]  Richard S. J. Frackowiak,et al.  The use of positron emission tomography in the clinical assessment of dementia. , 1992, Seminars in nuclear medicine.

[53]  C. DeCarli,et al.  What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? , 2007, Neurology.

[54]  T. Rasmussen,et al.  Histopathology of nonneoplastic lesions in frontal lobe epilepsy. Review of 180 cases with recent MRI and PET correlations. , 1992, Advances in neurology.

[55]  D Comar,et al.  Differential diagnosis of Alzheimer's disease with PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  B. Levin,et al.  Predominant left hemisphere metabolic dysfunction in dementia. , 1989, Archives of neurology.

[57]  A. Alavi,et al.  A Metabolic Imaging Severity Rating Scale for the Assessment of Cognitive Impairment , 2003, Clinical nuclear medicine.

[58]  M E Phelps,et al.  Patterns of human local cerebral glucose metabolism during epileptic seizures. , 1982, Science.

[59]  B. Choe,et al.  Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. , 2004, European journal of radiology.

[60]  Cesar C. Santos,et al.  18‐FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN CHILDREN AND ADOLESCENTS WITH TRAUMATIC BRAIN INJURY , 1995 .

[61]  M. Raichle,et al.  [18F]-labeled 3-deoxy-3-fluoro-D-glucose: synthesis and preliminary biodistribution data. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  S. Folstein,et al.  D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. , 1990, The Journal of neuropsychiatry and clinical neurosciences.

[63]  Jane S. Paulsen,et al.  Thalamic metabolism and symptom onset in preclinical Huntington's disease. , 2007, Brain : a journal of neurology.

[64]  V. Dhawan,et al.  Network modulation in the treatment of Parkinson's disease. , 2006, Brain : a journal of neurology.

[65]  M. Phelps,et al.  Dissociation of cerebral glucose metabolism and level of consciousness during the period of metabolic depression following human traumatic brain injury. , 2000, Journal of neurotrauma.

[66]  H. Fukuyama,et al.  Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy , 1997, Annals of neurology.

[67]  M. Mendez,et al.  Accuracy of the clinical evaluation for frontotemporal dementia. , 2007, Archives of neurology.

[68]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[69]  Michael E. Phelps,et al.  Comparative localization of foci in partial epilepsy by PCT and EEG , 1982 .

[70]  J. Mazziotta,et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.

[71]  H. Kung Overview of radiopharmaceuticals for diagnosis of central nervous disorders. , 1991, Critical reviews in clinical laboratory sciences.

[72]  D Comar,et al.  Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[73]  Andrew Newberg,et al.  Neuroimaging of traumatic brain injury. , 2008, Seminars in neurology.

[74]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[75]  B Horwitz,et al.  Relation of measured brain glucose utilisation and cerebral atrophy in man. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[76]  保坂 加代 Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration , 2003 .

[77]  R Harrop,et al.  Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease , 1986, Neurology.

[78]  D. Brooks,et al.  Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.

[79]  Sébastien Ourselin,et al.  Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging , 2008, NeuroImage.

[80]  K. Leenders,et al.  Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride , 1997, Movement disorders : official journal of the Movement Disorder Society.

[81]  Y Agid,et al.  Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. , 1985, Brain : a journal of neurology.

[82]  Lisa A. Weissfeld,et al.  Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.

[83]  C. Marsden BASAL GANGLIA DISEASE , 1982, The Lancet.

[84]  W. Theodore,et al.  Patterns of cerebral glucose metabolism in patients with partial seizures , 1988, Neurology.

[85]  Takayuki Kato,et al.  Statistical image analysis of cerebral glucose metabolism in patients with cognitive impairment following diffuse traumatic brain injury. , 2007, Journal of neurotrauma.

[86]  E. Hoffman,et al.  TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.

[87]  P. Van Bogaert,et al.  Statistical Parametric Mapping of Regional Glucose Metabolism in Mesial Temporal Lobe Epilepsy , 2000, NeuroImage.

[88]  J. Haxby,et al.  Anatomic, metabolic, neuropsychological, and molecular genetic studies of three pairs of identical twins discordant for dementia of the Alzheimer's type. , 1991, Archives of neurology.

[89]  D. Eidelberg,et al.  Abnormal metabolic networks in atypical parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.

[90]  Conrad V. Kufta,et al.  Temporal lobectomy for uncontrolled seizures: The role of positron emission tomography , 1992, Annals of neurology.

[91]  W. Jagust,et al.  Regional cerebral glucose transport and utilization in Alzheimer's disease , 1989, Neurology.

[92]  P. Mcgeer,et al.  Cortical glucose metabolism in parkinson's and alzheimer's disease , 1990, Journal of neuroscience research.

[93]  C. Rowe,et al.  The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias , 2008, Molecular Neurobiology.

[94]  Nir Giladi,et al.  Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome. , 1993, Advances in neurology.

[95]  Sanjiv S. Gambhir,et al.  Positron Emission Tomography in Evaluation of Dementia , 2001 .

[96]  S. Gilman,et al.  Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.

[97]  Matthias Reimold,et al.  [11C]PIB binding in Parkinson's disease dementia , 2008, NeuroImage.

[98]  R. Grossman,et al.  MR imaging of Parkinson disease with spin-echo and gradient-echo sequences. , 1988, AJR. American journal of roentgenology.

[99]  T. Vogt,et al.  The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[100]  A. Alavi,et al.  Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[101]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[102]  G. Alexander,et al.  Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. , 2008, Archives of neurology.

[103]  M. Seller SCREENING FOR NEURAL-TUBE DEFECTS , 1975, The Lancet.

[104]  J. Haxby,et al.  Relations between Neuropsychological and Cerebral Metabolic Asymmetries in Early Alzheimer's Disease , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[105]  Keith A. Johnson,et al.  Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.

[106]  W. Snow,et al.  The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease , 1988, Neurology.

[107]  J. Haxby,et al.  Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease , 1985, Annals of neurology.

[108]  J. Baron,et al.  Mild cognitive impairment , 2003, Neurology.

[109]  G. Sedvall,et al.  IN-VIVO DEMONSTRATION OF REDUCED BENZODIAZEPINE RECEPTOR BINDING IN HUMAN EPILEPTIC FOCI , 1988, The Lancet.

[110]  Schwartz,et al.  Neuroimaging in Closed Head Injury. , 1997, Seminars in Clinical Neuropsychiatry.

[111]  R. Frackowiak PET: Studies in dementia , 1989, Psychiatry Research.

[112]  Luigi Mansi,et al.  Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography , 1984, Annals of neurology.

[113]  M. Reivich,et al.  Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease , 1998, Annals of neurology.

[114]  Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study , 2007, Journal of Neural Transmission.

[115]  H. Fukuyama,et al.  Cerebral glucose metabolism in corticobasal degeneration: Comparison with progressive supranuclear palsy and normal controls , 1997, Movement disorders : official journal of the Movement Disorder Society.

[116]  M. Sasaki,et al.  Differentiating between multiple system atrophy and Parkinson’s disease by positron emission tomography with18F-dopa and18F-FDG , 1997, Annals of nuclear medicine.

[117]  M. D. de Leon,et al.  Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[118]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[119]  H. Engler,et al.  In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[120]  Sid Gilman,et al.  Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy , 1987, Annals of neurology.

[121]  A. Convit,et al.  Reduced hippocampal metabolism in MCI and AD , 2005, Neurology.

[122]  D. Eidelberg Positron emission tomography studies in parkinsonism. , 1992, Neurologic clinics.

[123]  Sid Gilman,et al.  Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography , 1988, Annals of neurology.

[124]  Timo Grimmer,et al.  Clinical severity of Alzheimer's disease is associated with PIB uptake in PET , 2009, Neurobiology of Aging.

[125]  D. Eidelberg,et al.  [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.

[126]  A Drzezga,et al.  Reduction of Benzodiazepine Receptor Binding is Related to the Seizure Onset Zone in Extratemporal Focal Cortical Dysplasia , 2000, Epilepsia.

[127]  T Jones,et al.  The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. , 1990, Archives of neurology.

[128]  J R Moeller,et al.  The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies , 1990, Movement disorders : official journal of the Movement Disorder Society.

[129]  J. Haxby,et al.  Positron emission tomography in Alzheimer's disease , 1986, Neurology.

[130]  J C Froment,et al.  Positron Emission Tomography Metabolic Data Corrected for Cortical Atrophy Using Magnetic Resonance Imaging , 1996, Alzheimer disease and associated disorders.

[131]  B. Maziére,et al.  Positron emission tomography studies of brain receptors , 1991, Fundamental & clinical pharmacology.

[132]  M. Hayden,et al.  Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.

[133]  A. Drzezga,et al.  Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study , 2007, Neurobiology of Aging.

[134]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[135]  I. Savic,et al.  Cortical Benzodiazepine Receptor Changes are Related to Frequency of Partial Seizures: A Positron Emission Tomography Study , 1996, Epilepsia.

[136]  A. Alavi,et al.  Fluorine-18-FDG evaluation of crossed cerebellar diaschisis in head injury. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[137]  R. Hichwa,et al.  PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.

[138]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[139]  O. Muzik,et al.  Glucose and [11C]flumazenil positron emission tomography abnormalities of thalamic nuclei in temporal lobe epilepsy , 1999, Neurology.

[140]  K Herholz,et al.  Positron emission tomography imaging in dementia. , 2007, The British journal of radiology.

[141]  V. Dhawan,et al.  Changes in network activity with the progression of Parkinson's disease. , 2007, Brain : a journal of neurology.

[142]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[143]  A. Alavi,et al.  Predictors of outcome after anterior temporal lobectomy , 1994, Neurology.

[144]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[145]  C. Nahmias,et al.  Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease , 1984, Journal of the Neurological Sciences.

[146]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[147]  T. Taniwaki,et al.  Positron emission tomographic (PET) studies in dementia , 1993, Journal of the Neurological Sciences.

[148]  A. Drzezga,et al.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[149]  S. Gilman,et al.  Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy , 1994, Annals of neurology.

[150]  R. Hichwa,et al.  Normal caudate glucose metabolism in persons at risk for Huntington??s disease , 1987 .

[151]  S. DeKosky,et al.  Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.

[152]  B. Miller,et al.  11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.

[153]  R. Coleman,et al.  Temporal lobe hypometabolism on PET , 1993, Neurology.

[154]  J C Mazziotta,et al.  Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.

[155]  S. Sato,et al.  Relation of EEG alpha background to parietal lobe function in Alzheimer's disease as measured by positron emission tomography and psychometry , 1988, Neurology.

[156]  M. Richardson,et al.  Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: An 11C‐flumazenil PET study , 1996, Annals of neurology.

[157]  A. Bol,et al.  Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy , 1989, Annals of neurology.

[158]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[159]  N. Nakayama,et al.  Focal brain glucose hypometabolism in patients with neuropsychologic deficits after diffuse axonal injury. , 2007, AJNR. American journal of neuroradiology.

[160]  W. Jagust,et al.  The diagnosis of Alzheimer-type dementia. A preliminary comparison of positron emission tomography and proton magnetic resonance. , 1984, JAMA.

[161]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[162]  J. Mann,et al.  Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease , 2008, Journal of Nuclear Medicine.

[163]  A J Lees,et al.  Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. , 1988, Brain : a journal of neurology.

[164]  G. Fein,et al.  Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy , 1997, Annals of neurology.

[165]  B Horwitz,et al.  Abnormal brain glucose metabolism in Alzheimer's disease, as measured by position emission tomography. , 1991, Advances in experimental medicine and biology.

[166]  M. Mintun,et al.  Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. , 2008, Archives of neurology.

[167]  P. Scheltens,et al.  Advances in the early detection of Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[168]  R. Kessler,et al.  Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography. , 1996, Investigative radiology.

[169]  Olli Eskola,et al.  [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease , 2001 .

[170]  W. J. Brown,et al.  Pathological findings underlying focal temporal lobe hypometabolism in partial epilepsy , 1982, Annals of neurology.

[171]  M E Phelps,et al.  Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. , 1997, Journal of neurosurgery.

[172]  A. Alavi,et al.  18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. , 1982, The American journal of psychiatry.

[173]  J B Poline,et al.  Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. , 2007, Brain : a journal of neurology.

[174]  V. Sossi,et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[175]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[176]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[177]  C. Nahmias,et al.  Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[178]  M. Iyo,et al.  Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for β‐CFT binding with positron emission tomography , 1999, Annals of neurology.

[179]  H. Lüders,et al.  Outcome of temporal lobe epilepsy surgery predicted by statistical parametric PET imaging. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[180]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[181]  D. Selkoe,et al.  Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases , 1988, Annals of neurology.

[182]  W D Heiss,et al.  STN-DBS activates the target area in Parkinson disease , 2008, Neurology.

[183]  D A Shewmon,et al.  Ictal Patterns of Cerebral Glucose Utilization in Children with Epilepsy , 1994, Epilepsia.

[184]  G. Fink,et al.  Positron emission tomography in the differential diagnosis of organic dementias. , 1991, Journal of neural transmission. Supplementum.

[185]  J. Rinne,et al.  Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT , 2000, Annals of neurology.

[186]  J. Cummings,et al.  Alzheimer's disease , 1998, Neurology.

[187]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[188]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.